AU2023265031A1 - Bag3 and protein quality control in the brain - Google Patents
Bag3 and protein quality control in the brain Download PDFInfo
- Publication number
- AU2023265031A1 AU2023265031A1 AU2023265031A AU2023265031A AU2023265031A1 AU 2023265031 A1 AU2023265031 A1 AU 2023265031A1 AU 2023265031 A AU2023265031 A AU 2023265031A AU 2023265031 A AU2023265031 A AU 2023265031A AU 2023265031 A1 AU2023265031 A1 AU 2023265031A1
- Authority
- AU
- Australia
- Prior art keywords
- bag3
- vector
- brain
- promoter
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337914P | 2022-05-03 | 2022-05-03 | |
| US63/337,914 | 2022-05-03 | ||
| PCT/US2023/020659 WO2023215266A1 (en) | 2022-05-03 | 2023-05-02 | Bag3 and protein quality control in the brain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023265031A1 true AU2023265031A1 (en) | 2024-11-28 |
Family
ID=88646932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023265031A Pending AU2023265031A1 (en) | 2022-05-03 | 2023-05-02 | Bag3 and protein quality control in the brain |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250289858A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4518882A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025514489A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250010008A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119255814A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023265031A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250880A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024003318A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316559A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013495A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215266A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024265705A1 (en) * | 2023-05-02 | 2025-11-20 | Research Institute At Nationwide Children's Hospital | Gene therapy for treatment of protein misfolding diseases |
| CN120478386B (zh) * | 2025-07-18 | 2025-10-17 | 南京大学 | 一种用于预防、改善和/或治疗阿尔茨海默症的siRNA及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1323733A1 (en) * | 2001-12-28 | 2003-07-02 | Arturo Leone | BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
| WO2015117010A2 (en) * | 2014-01-31 | 2015-08-06 | Temple University Of The Commonwealth System Of Higher Education | Bag3 as a target for therapy of heart failure |
| CN109937045A (zh) * | 2016-08-11 | 2019-06-25 | 天普大学-联邦高等教育系统 | 局部缺血/再灌注损伤 |
| US20210353613A1 (en) * | 2018-10-19 | 2021-11-18 | Aclipse One Inc. | Treatment of neurological disease |
| JP7595006B2 (ja) * | 2018-11-04 | 2024-12-05 | フィジーン、エルエルシー | 脳卒中、慢性外傷性脳症、及び外傷性脳損傷を含む脳性低酸素症の治療 |
| US20220088127A1 (en) * | 2019-01-15 | 2022-03-24 | Temple University - Of The Commonwealth System Of Higher Education | Targeting the bag family for the treatment of neurodegenerative disease |
| WO2023069744A1 (en) * | 2021-10-22 | 2023-04-27 | Temple University Of The Commonwealth System Of Higher Education | Bag3 methods and uses for treatment of inflammation |
-
2023
- 2023-05-02 WO PCT/US2023/020659 patent/WO2023215266A1/en not_active Ceased
- 2023-05-02 CA CA3250880A patent/CA3250880A1/en active Pending
- 2023-05-02 JP JP2024564848A patent/JP2025514489A/ja active Pending
- 2023-05-02 IL IL316559A patent/IL316559A/en unknown
- 2023-05-02 EP EP23799909.9A patent/EP4518882A4/en active Pending
- 2023-05-02 KR KR1020247039888A patent/KR20250010008A/ko active Pending
- 2023-05-02 AU AU2023265031A patent/AU2023265031A1/en active Pending
- 2023-05-02 CN CN202380037961.7A patent/CN119255814A/zh active Pending
- 2023-05-02 US US18/861,495 patent/US20250289858A1/en active Pending
-
2024
- 2024-10-29 CL CL2024003318A patent/CL2024003318A1/es unknown
- 2024-10-31 MX MX2024013495A patent/MX2024013495A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025514489A (ja) | 2025-05-02 |
| EP4518882A1 (en) | 2025-03-12 |
| IL316559A (en) | 2024-12-01 |
| CA3250880A1 (en) | 2023-11-09 |
| US20250289858A1 (en) | 2025-09-18 |
| KR20250010008A (ko) | 2025-01-20 |
| EP4518882A4 (en) | 2026-04-22 |
| WO2023215266A1 (en) | 2023-11-09 |
| MX2024013495A (es) | 2025-02-10 |
| CL2024003318A1 (es) | 2025-03-21 |
| CN119255814A (zh) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3146982B1 (en) | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders | |
| EP3132042B1 (en) | A method of treating peripheral neuropathies and motor neuron diseases | |
| EP4518882A1 (en) | Bag3 and protein quality control in the brain | |
| US10849991B2 (en) | Gene therapy for the treatment of a disease of retinal cone cells | |
| JP7759174B2 (ja) | 繊毛病のための遺伝子治療 | |
| US12583902B2 (en) | DNA-binding domain transactivators and uses thereof | |
| CA3203748A1 (en) | Products and methods for inhibition of expression of peripheral myelin protein-22 | |
| TW202136515A (zh) | 用於治療韓特氏病之腺相關病毒載體 | |
| US20250345464A1 (en) | Gene therapy for treating neurodegenerative diseases | |
| EP4286521A1 (en) | Gene therapy for treating neurodegenerative diseases | |
| US20230203534A1 (en) | Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy | |
| WO2024245120A1 (en) | Recombinant aav vectors for treating proteinopathies in central nervous system | |
| US20260007774A1 (en) | Aav-mediated delivery of rgs10 to microglia | |
| WO2025076201A1 (en) | Human-targeted zinc finger protein to treat angelman syndrome | |
| WO2024102961A1 (en) | Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same |